RAPP

Rapport Therapeutics Inc

28.99

Oct 13 • 3:59 PM ET -1.16 (-3.85%)

28.99

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: DNLI ACAD XENE KYMR CRNX AXSM INCY KRYS BIIB NBIX

| Held by: VTI IWM VXF VTWO IWO IBB DFAS XPH SCHA VHT

Scroll to Statements

Index	RUT
Market Cap	1.39B
Enterprise Value	964.82M
Income	-137.16M
Sales	20.00M
Book/sh	8.82
Cash/sh	9.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	84
IPO	Jun 07, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	69.54
P/B	3.29
P/C	3.19
P/FCF	-
EV/EBITDA	-
EV/Sales	48.24
Quick Ratio	15.72
Current Ratio	15.72
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-3.04
EPS next Y	-4.86
EPS next Q	-1.21
EPS this Y	-41.28%
EPS next Y	-20.28%
EPS next 5Y	-24.51%
EPS past 3/5Y	-114.24% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-23.53%
Sales Y/Y TTM	-
EPS Q/Q	-58.13%
Sales Q/Q	-
Earnings	Aug 05 BMO
EPS/Sales Surpr.	-23.56% -

Insider Own	39.96%
Insider Trans	-5.28%
Inst Own	75.32%
Inst Trans	0.72%
ROA	-36.85%
ROE	-39.96%
ROIC	-31.86%
Gross Margin	95.20%
Oper. Margin	-767.58%
Profit Margin	-685.80%
SMA20	-15.44%
SMA50	-30.93%
SMA200	-19.00%
Trades

Shs Outstand	47.96M
Shs Float	28.81M
Short Float	11.09%
Short Ratio	9.08
Short Interest	3.19M
52W High	52.93 -45.23%
52W Low	23.75 22.06%
Volatility	4.12% 6.77%
ATR (14)	2.07
RSI (14)	22.12
Beta	1.19
Rel Volume	0.88
Avg Volume	351.92K
Volume	309,982

Perf Week	-6.93%
Perf Month	-34.11%
Perf Quarter	-27.40%
Perf Half Y	-19.81%
Perf YTD	-4.45%
Perf Year	10.69%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	63.23
Prev Close	30.15
Price	28.99
Change %	-3.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-26	Initiated	Guggenheim	Buy	$65
Jul-28-26	Initiated	William Blair	Outperform
Jun-24-26	Initiated	Leerink Partners	Outperform	$52
May-19-26	Resumed	Truist	Buy	$56
Apr-10-26	Initiated	Raymond James	Strong Buy	$66
Feb-02-26	Initiated	Wells Fargo	Overweight	$43
Nov-19-25	Initiated	BTIG Research	Buy	$47
Sep-16-25	Initiated	Truist	Buy	$44
Aug-06-25	Initiated	H.C. Wainwright	Buy	$31
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Show Previous Ratings

Sep-02-26 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-26 07:00AM	Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program (GlobeNewswire)
Aug-05-26 07:00AM	Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update (GlobeNewswire)
May-20-26 04:05PM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-07-26 07:00AM	Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update (GlobeNewswire) +7.74%
04:30PM	Loading…
Apr-21-26 04:30PM	Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting (GlobeNewswire)
Apr-01-26 07:00AM	Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-10-26 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-09-26 09:26AM	Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures (Benzinga)
07:00AM	Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China (GlobeNewswire)
Feb-24-26 04:05PM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-07-26 07:00AM	Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline (GlobeNewswire) +8.89%
Dec-18-25 07:00AM	Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-25 12:00PM	Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know (Zacks)
Dec-05-25 09:00AM	Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures (GlobeNewswire)
09:55AM	Loading…
Nov-28-25 09:55AM	Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? (Zacks)
Nov-25-25 07:00AM	Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-12-25 09:55AM	Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet (Zacks)
Nov-06-25 07:00AM	Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Nov-05-25 04:05PM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-30-25 11:49AM	JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success (Insider Monkey) +6.19%
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 04:05PM	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (GlobeNewswire)
Sep-09-25 09:17PM	Rapport Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.93% -20.09%
Sep-08-25 04:08PM	Rapport Stock Doubles After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily) +119.15%
04:05PM	Rapport Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:45AM	Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily)
09:28AM	Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year (Benzinga)
06:00AM	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures (GlobeNewswire)
Sep-05-25 04:05PM	Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 (GlobeNewswire) -6.45%
08:03AM	Loading…
Aug-13-25 08:03AM	Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors (Business Wire)
Aug-07-25 07:00AM	Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update (GlobeNewswire) +5.48%
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat) -7.93%
Jun-02-25 02:45PM	Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates (GlobeNewswire) +13.66%
May-27-25 07:00AM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) -7.21%
May-21-25 07:00AM	Rapport Therapeutics to Host 2025 Investor and Analyst Day (GlobeNewswire)
May-08-25 07:00AM	Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Apr-22-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.27%
Mar-31-25 04:33AM	Rapport Therapeutics: Too Early To Be Interesting (Seeking Alpha)
Mar-21-25 07:00AM	Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-11-25 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +8.34%
Mar-03-25 07:00AM	Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development (GlobeNewswire) -28.71%
Feb-24-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:20AM	Rapport Therapeutics announces new Phase 1 data for RAP-219 (TipRanks) -11.26%
Jan-09-25 09:12AM	CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
07:00AM	Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
Dec-06-24 12:01PM	Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures (GlobeNewswire)
Nov-14-24 07:00AM	Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-08-24 07:18AM	Rapport Therapeutics expects cash to fund requirements through 2026 (TipRanks)
Nov-07-24 07:00AM	Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update (GlobeNewswire)
Nov-04-24 07:00AM	Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Founder & Independent ChairmanDr. Steven M. Paul M.D.

CEOMr. Abraham N. Ceesay M.B.A.

Chief Financial OfficerMr. Troy A. Ignelzi

Chief Medical OfficerDr. Jeffrey Sevigny M.D.

Ph.D.Dr. David Bredt M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ceesay Abraham	Chief Executive Officer	Oct 06 '26	Sale	32.03	3,375	108,106	453,392	Oct 08 04:07 PM
Ceesay Abraham	Chief Executive Officer	Oct 07 '26	Sale	30.66	1,147	35,167	452,245	Oct 08 04:07 PM
Abraham N. Ceesay	Officer	Oct 06 '26	Proposed Sale	31.15	39,470	1,229,490		Oct 06 06:18 PM
Gault Cheryl	Chief Operating Officer	Sep 30 '26	Sale	33.19	10,000	331,856	139,914	Oct 01 04:30 PM
CHERYL GAULT	Officer	Sep 30 '26	Proposed Sale	33.02	10,000	330,200		Sep 30 04:20 PM
Ceesay Abraham	Chief Executive Officer	Sep 23 '26	Sale	39.17	2,210	86,565	456,767	Sep 24 04:05 PM
Ceesay Abraham	Chief Executive Officer	Sep 08 '26	Sale	45.61	8,210	374,498	458,977	Sep 09 04:05 PM
Ceesay Abraham	Chief Executive Officer	Aug 25 '26	Sale	49.57	18,921	937,957	467,187	Aug 26 04:05 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Aug 25 '26	Sale	50.64	37,000	1,873,605	195,862	Aug 26 04:00 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Aug 24 '26	Sale	50.00	13,160	657,978	232,862	Aug 26 04:00 PM
KRISHNASWAMY YELESWARAM	Officer	Aug 25 '26	Proposed Sale	49.33	37,000	1,825,210		Aug 25 04:29 PM
KRISHNASWAMY YELESWARAM	Officer	Aug 24 '26	Proposed Sale	48.24	11,472	553,409		Aug 24 04:28 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Aug 19 '26	Sale	49.90	404	20,160	246,022	Aug 20 04:09 PM
KRISHNASWAMY YELESWARAM	Officer	Aug 19 '26	Proposed Sale	49.01	2,092	102,529		Aug 19 04:38 PM
Ceesay Abraham	Chief Executive Officer	Aug 11 '26	Sale	48.01	28,958	1,390,405	486,108	Aug 12 04:35 PM
Ceesay Abraham	Chief Executive Officer	Aug 10 '26	Sale	46.26	22,541	1,042,772	515,066	Aug 12 04:35 PM
Ceesay Abraham	Chief Executive Officer	Jul 27 '26	Sale	42.11	2,210	93,061	537,607	Jul 29 04:05 PM
Ceesay Abraham	Chief Executive Officer	Jul 14 '26	Sale	40.00	8,210	328,437	539,817	Jul 15 04:15 PM
Gault Cheryl	Chief Operating Officer	Jun 30 '26	Sale	41.58	10,000	415,798	149,914	Jul 01 04:10 PM
Ceesay Abraham	Chief Executive Officer	Jun 29 '26	Sale	39.83	8,220	327,398	548,027	Jul 01 04:05 PM
CHERYL GAULT	Officer	Jun 30 '26	Proposed Sale	40.39	10,000	403,900		Jun 30 04:33 PM
Abraham N. Ceesay	Officer	Jun 29 '26	Proposed Sale	40.39	99,480	4,017,997		Jun 29 04:45 PM
Third Rock Ventures V, L.P.	10% Owner	May 26 '26	Sale	40.05	18,572	743,753	6,280,525	May 28 04:15 PM
Third Rock Ventures V, L.P.	10% Owner	May 26 '26	Proposed Sale	40.00	18,572	742,880		May 27 09:16 AM
Third Rock Ventures V, L.P.	10% Owner	May 11 '26	Sale	40.24	133,618	5,377,323	6,299,097	May 13 07:06 PM
Third Rock Ventures V, L.P.	10% Owner	May 07 '26	Sale	40.12	271,495	10,892,651	6,437,733	May 11 05:07 PM
Third Rock Ventures V, L.P.	10% Owner	May 08 '26	Sale	40.31	5,018	202,256	6,432,715	May 11 05:07 PM
Third Rock Ventures V, L.P.	10% Owner	May 11 '26	Proposed Sale	40.25	133,618	5,378,124		May 11 04:25 PM
Third Rock Ventures V, L.P.	10% Owner	May 08 '26	Proposed Sale	40.31	5,018	202,254		May 08 04:57 PM
Third Rock Ventures V, L.P.	10% Owner	May 07 '26	Proposed Sale	40.12	271,495	10,892,705		May 07 04:44 PM
Third Rock Ventures V, L.P.	10% Owner	Apr 17 '26	Sale	40.32	426,005	17,175,244	6,709,228	Apr 21 07:36 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 17 '26	Sale	39.99	20,225	808,844	246,426	Apr 21 04:55 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 17 '26	Proposed Sale	39.54	20,225	799,696		Apr 17 04:37 PM
Third Rock Ventures V, L.P.	10% Owner	Apr 17 '26	Proposed Sale	40.32	426,005	17,175,116		Apr 17 04:25 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 14 '26	Sale	35.08	10,200	357,797	266,651	Apr 14 04:13 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 13 '26	Sale	34.97	9,165	320,537	276,851	Apr 14 04:13 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 10 '26	Sale	34.98	500	17,490	286,016	Apr 14 04:13 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 13 '26	Proposed Sale	34.17	19,365	661,702		Apr 13 04:37 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 10 '26	Proposed Sale	34.22	500	17,110		Apr 10 04:34 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 08 '26	Sale	34.90	360	12,564	286,516	Apr 09 04:30 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 08 '26	Proposed Sale	33.49	360	12,056		Apr 08 05:35 PM
Gault Cheryl	Chief Operating Officer	Mar 30 '26	Sale	28.19	10,000	281,857	159,914	Mar 31 04:27 PM
CHERYL GAULT	Officer	Mar 30 '26	Proposed Sale	27.84	10,000	278,400		Mar 30 05:31 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Mar 25 '26	Sale	29.99	10,115	303,355	286,876	Mar 26 04:41 PM
KRISHNASWAMY YELESWARAM	Officer	Mar 25 '26	Proposed Sale	28.25	10,115	285,749		Mar 25 04:22 PM
Gault Cheryl	Chief Operating Officer	Mar 05 '26	Sale	28.93	2,014	58,265	169,914	Mar 09 04:07 PM
Gault Cheryl	Officer	Mar 05 '26	Proposed Sale	28.92	2,014	58,236		Mar 05 05:54 PM
Ceesay Abraham	Chief Executive Officer	Feb 18 '26	Sale	29.34	5,833	171,161	556,247	Feb 19 07:06 PM
Ceesay Abraham	Chief Executive Officer	Feb 18 '26	Sale	29.36	5,083	149,212	20,729	Feb 19 07:06 PM
Bredt David	Chief Scientific Officer	Feb 19 '26	Option Exercise	1.80	6,000	10,800	393,075	Feb 19 07:05 PM
Bredt David	Chief Scientific Officer	Feb 17 '26	Sale	29.02	8,500	246,655	387,075	Feb 19 07:05 PM
Ceesay Abraham	Chief Executive Officer	Jan 20 '26	Sale	26.12	5,833	152,333	562,080	Jan 22 07:00 PM
Ceesay Abraham	Chief Executive Officer	Jan 20 '26	Sale	26.11	5,083	132,737	25,812	Jan 22 07:00 PM
Bredt David	Chief Scientific Officer	Jan 15 '26	Sale	26.84	8,500	228,132	395,575	Jan 16 04:06 PM
DAVID BREDT	Officer	Jan 15 '26	Proposed Sale	27.42	17,000	466,140		Jan 15 04:28 PM
Bredt David	Chief Scientific Officer	Dec 31 '25	Sale	30.05	6,567	197,338	404,075	Jan 05 04:20 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Dec 31 '25	Sale	30.05	2,840	85,342	296,991	Jan 05 04:19 PM
DAVID BREDT	Officer	Jan 02 '26	Proposed Sale	30.05	6,567	197,338		Jan 02 08:20 PM
Krishnaswamy Yeleswaram	Officer	Jan 02 '26	Proposed Sale	30.05	2,840	85,343		Jan 02 08:17 PM
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.64	5,833	172,877	567,913	Dec 18 04:11 PM
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.63	5,083	150,632	30,895	Dec 18 04:11 PM
THE DOROTHY CEESAY IRREVOCABLE	Director	Dec 17 '25	Proposed Sale	30.76	15,249	469,059		Dec 17 04:28 PM
ABRAHAM CEESAY	Director	Dec 17 '25	Proposed Sale	30.76	17,499	538,269		Dec 17 04:25 PM
Bredt David	Chief Scientific Officer	Dec 15 '25	Sale	30.02	8,500	255,130	392,642	Dec 16 05:07 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Option Exercise	1.80	5,000	9,000	176,928	Dec 01 04:17 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Sale	30.10	5,000	150,486	171,928	Dec 01 04:17 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.19	5,833	146,931	573,746	Nov 18 04:27 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.20	5,083	128,116	35,978	Nov 18 04:27 PM
Bredt David	Chief Scientific Officer	Nov 17 '25	Sale	25.19	8,500	214,091	401,142	Nov 18 04:24 PM
Bredt David	Chief Scientific Officer	Oct 15 '25	Sale	25.79	8,500	219,196	409,642	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,833	150,541	579,579	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,083	131,189	41,061	Oct 16 04:30 PM
DAVID BREDT	Officer	Oct 15 '25	Proposed Sale	24.88	25,500	634,440		Oct 15 04:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RAPP

Rapport Therapeutics Inc

Upgrade your Finviz experience